Use of transdermal amitriptyline gel in a patient with chronic pain and depression.
A man with severe inflammatory bowel disease suffered from chronic abdominal pain and depression. A transdermal amitriptyline gel preparation was compounded since he was unable to take drugs orally Serum concentrations of amitriptyline and its active metabolite nortriptyline were measured over 24 hours. Symptoms of depression were monitored before starting transdermal therapy and at the end of 6 weeks. Pain symptoms and amitriptyline adverse drug events were monitored daily Steady-state serum concentrations of drug and metabolite were within the therapeutic range over 24 hours. The patient reported that his mood was improved but his abdominal pain remained unchanged. Transdermal amitriptyline gel was well tolerated and is an alternative delivery system in patients unable to take drugs orally.
Scott
M A
MA
Department of Pharmacy Practice, Campbell University School of Pharmacy, Buies Creek, North Carolina 27506, USA.
Letrent
K J
KJ
Hager
K L
KL
Burch
J L
JL
D000279:Administration, Cutaneous; D000328:Adult; D000639:Amitriptyline / Q000008:administration & dosage*; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage*; D002908:Chronic Disease; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005782:Gels; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000209:etiology
D000929:Antidepressive Agents, Tricyclic; D005782:Gels; D000639:Amitriptyline